Substance and claimed effects

Refractive surgery is the category of elective procedures that permanently change the eye's focusing power so the patient no longer needs glasses or contacts. Five real-world modalities matter: LASIK (a femtosecond laser lifts a thin corneal flap, an excimer laser reshapes the stromal bed underneath, the flap is replaced); PRK (the corneal epithelium is removed and the surface reshaped — no flap, longer healing); SMILE (a femtosecond laser sculpts a lenticule inside the cornea and removes it through a small incision); phakic IOLs, principally the ICL (a soft lens implanted between the iris and the natural lens — used for high myopia where the cornea is too thin to ablate); and refractive lens exchange (RLE) (the natural lens is removed and replaced with a multifocal or extended-depth-of-focus IOL — chiefly for presbyopia from age ~50). LASIK dominates volume globally; SMILE and ICL have grown sharply since 2015 Kim et al. 2019. Claimed effects: correction of myopia, hyperopia and astigmatism within the device's labelled range; uncorrected vision ≥20/40 in ~95–99% of treated eyes and ≥20/20 in the majority; one-time intervention with stable outcomes out to 10+ years; ≥95% patient satisfaction across pooled literature Solomon et al. 2009. The entry covers all five modalities and every meaningful consequence: glasses-free function in daily life, the dry-eye / glare / halo signature, the candidacy gate, and the rare but real complication tail (ectasia, infection, regression, flap injury).

Evidence by addressing question

Mechanism

The eye focuses by bending light at two surfaces — the cornea (most of the work) and the natural crystalline lens (the fine adjustment) — onto the retina. Refractive error is a mismatch between that combined optical power and the eyeball's length: a too-long eye over-focuses (myopia), a too-short eye under-focuses (hyperopia), and an irregularly curved cornea splits the focus along two axes (astigmatism). Corneal laser surgery (LASIK, PRK, SMILE) flattens or steepens the front surface so the existing eyeball length is now correctly matched: a microns-thin layer of stromal collagen is removed per the wavefront-driven treatment map. The Munnerlyn formula sets the depth: roughly 12 µm of tissue per diopter for a 6 mm optical zone Kim et al. 2019. Phakic IOLs and RLE work upstream — they add or substitute a lens of calculated power, leaving the cornea untouched (preferred when the cornea is too thin or the refractive error too large for laser ablation). None of these procedures fixes presbyopia unless an RLE with a multifocal IOL is chosen — and that route has its own optical compromises (halos, contrast loss).

Evidence

The literature is unusually deep for an elective procedure. The American Academy of Ophthalmology's safety and efficacy report on LASIK for myopia and astigmatism, pooling trial data, established uncorrected distance vision ≥20/40 in 92–98% of treated eyes and ≥20/20 in 60–82% across modern devices Sugar et al. 2002. A 2016 modern-era pooled review of 67 LASIK studies (≈68,000 eyes) found ≥20/40 in 99.5% and patient satisfaction at 98.6% Sandoval et al. 2016. The PROWL-1 and PROWL-2 studies — the FDA's own patient-reported outcomes cohorts (n=574) — showed visual satisfaction ≥98% at 3 months, with the caveat below in §failure-modes Eydelman et al. 2017. Long-term durability: a single-institution audit of 37,932 myopic LASIK eyes followed prospectively for ten years showed sustained ≥20/40 in 94% and a low retreatment rate Yuen et al. 2010; a separate 10-year European cohort of LASIK for myopia up to −10 D documented mild regression (≈0.5 D over a decade) but stable function Alió et al. 2008. Comparative satisfaction against the reader's likely current alternative: a three-year longitudinal survey found LASIK patients reported higher satisfaction with their vision correction than long-term contact lens wearers, with the gap widening over time Price et al. 2016. SMILE in low-to-moderate myopia produces visual outcomes statistically comparable to LASIK with a smaller corneal nerve disruption Reinstein et al. 2014. The ICL central-port (EVO) literature shows ≥20/20 uncorrected in 80–90% of high-myopia eyes (−6 to −18 D) with stable refraction at 5+ years Packer 2018. The American Academy of Ophthalmology's Preferred Practice Pattern integrates this into a clinical-grade recommendation framework Chuck et al. 2018.

Protocol

LASIK and SMILE are typically same-day, both eyes, 15–30 minutes total chair time; topical anaesthetic drops only, no general anaesthesia. The patient sees clearly enough to function within 24 hours and is usually back at work in 1–2 days, with the final result stabilising over 1–3 months. PRK has the same long-term outcomes but a longer recovery: a bandage contact lens for 4–5 days, blur and discomfort for a week, and final stabilisation at 3 months. ICL is a 20–30 minute intraocular procedure per eye (often staged a week apart), faster visual recovery than PRK, and requires a peripheral iridotomy or central-port lens to prevent pupillary block. RLE is essentially modern cataract surgery on a clear lens — same 15-minute per-eye procedure, with intraocular lens calculation as the high-stakes step. All protocols include preoperative drops, postoperative antibiotic and steroid drops for 1–2 weeks, and follow-up at day 1, week 1, month 1, and quarterly. Sun protection (UV-blocking sunglasses) and avoidance of swimming pools / hot tubs for 2 weeks reduce infection risk Schallhorn et al. 2016. Retreatment ("enhancement") within the first 1–2 years is possible in 1–5% of cases when residual refractive error persists.

Contraindications

Absolute exclusions from corneal laser surgery: keratoconus or other corneal ectasia, active corneal infection or significant corneal scarring, severe dry eye, autoimmune disease with poor wound healing, uncontrolled diabetes, pregnancy or breastfeeding (refraction shifts), age under 18 (most surgeons set the floor at 21 to ensure refractive stability), and unstable refraction (Δ ≥0.5 D in the past 12 months). Strong relative contraindications: thin cornea (predicted residual stromal bed <250–300 µm), high refractive error beyond the device's labelled range, large pupil with high-order aberrations, prior herpetic keratitis. The Randleman ectasia risk score — a 0–9 scale combining topography, age, residual stromal bed, pachymetry, and refractive error — predicts post-LASIK ectasia with strong discriminatory power; scores ≥3 are high-risk and should not have LASIK (PRK or ICL preferred) Randleman et al. 2008. Suspected keratoconus on topography is the single most important catch — modern Scheimpflug imaging (Pentacam, Galilei) has dramatically reduced post-LASIK ectasia incidence by identifying these eyes preoperatively Chuck et al. 2018.

Failure modes

The honest complication tail, weighted by lived impact rather than rarity. Dry eye is the dominant and most-reported complaint. A meta-analysis pooling LASIK and SMILE found symptomatic dry eye in roughly 20–40% of patients at 6 months postoperatively, declining toward baseline by 12 months in most — SMILE produces meaningfully less dry eye than LASIK (the corneal nerves on the flap edge are spared) Kobashi et al. 2017. A subset — perhaps 5–10% — report persistent dry-eye symptoms beyond a year; severe chronic neurotrophic dry eye is rare but life-impacting Toda 2018. Visual disturbances — halos, glare, starbursts around lights, especially at night. In PROWL-1, 41% reported a new visual symptom at 3 months, but baseline rates with glasses and contacts were comparably high (most resolved by 6 months); 1–4% reported being bothered "very much" Eydelman et al. 2017. Ectasia — late corneal thinning that mimics keratoconus, presenting 6 months to 5 years post-LASIK. Incidence in screened modern cohorts is ≈0.04–0.6% per eye; treatment is corneal cross-linking and, in late cases, transplant Randleman et al. 2008. Infection (microbial keratitis) is rare — ~1 in 1,000 to 1 in 5,000 procedures Schallhorn et al. 2016, comparable to or lower than the annualised infection rate from daily soft-contact-lens wear (≈1 in 500 over a decade) Stapleton et al. 2008. Flap complications (dislocation, epithelial ingrowth, diffuse lamellar keratitis) occur in <1% with femtosecond flaps. Regression — mild return of refractive error — runs ~0.5 D over a decade in high myopes Alió et al. 2008. Loss of best-corrected vision by 2+ lines is rare (<1%) in modern devices Sandoval et al. 2016. ICL adds specific risks: lens vault errors, anterior subcapsular cataract (historically ~1% with older models, near-zero with central-port designs), pigment dispersion Packer 2018. RLE with multifocal IOLs adds the IOL itself as a permanent compromise — halos, contrast loss, and "neuro-adaptation" that takes months and never fully resolves in some.

Misconceptions

The most consequential: LASIK does not fix presbyopia and does not prevent it. A 28-year-old who has LASIK in 2024 will still need reading glasses around age 45. "Monovision" LASIK — one eye corrected for distance, the other left slightly myopic for near — is a partial answer but trades binocular vision quality for reading independence. Second: 20/20 is not "perfect". The Snellen chart measures high-contrast acuity in a clinic; it does not capture night vision, contrast sensitivity in fog, or the low-glare baseline a healthy young eye delivers. A subset of post-LASIK patients hit 20/20 yet describe their vision as subjectively worse than pre-op contacts — this is the "20/happy" vs "20/20" gap the AAO has flagged AAO 2022. Third: the FDA's 2022 draft labeling controversy was not "the FDA pulling LASIK" — it was a proposed patient-information leaflet that the AAO publicly disputed on the grounds that the dry-eye and quality-of-life figures cited were unrepresentative of modern outcomes FDA 2022 AAO 2022; LASIK remains FDA-approved and broadly endorsed by US ophthalmology. Fourth: SMILE is not "newer-therefore-better". SMILE has flap-free advantages for athletes and the dry-eye-prone, but in high-cylinder astigmatism and hyperopia the device range is narrower than LASIK; modality choice is patient-specific.

Alternatives

Within the surgical category, the right modality depends on the eye, not the brand. LASIK is the default for moderate myopia / hyperopia / astigmatism with a healthy cornea. PRK is preferred when the cornea is borderline thin, when occupation involves contact-sport eye-trauma risk (no flap to dislodge), and for the dry-eye prone (no flap-edge nerve cut) — at the cost of a slower recovery. SMILE is preferred for moderate myopia in dry-eye-prone patients and competitive athletes — smaller incision, less corneal nerve disruption Reinstein et al. 2014. ICL is the standard option for high myopia (>−8 D) and thin corneas — reversible (the lens can be removed if needed) Packer 2018. RLE is mostly for ages 50+, especially when presbyopia is already meaningful and the patient wants a one-procedure solution. Outside the surgical category, the alternatives are glasses (zero risk, ongoing cost), daily-disposable contacts (lower infection risk than monthly lenses, ongoing cost), orthokeratology (reversible, requires nightly compliance), and atropine for paediatric myopia control (not applicable to adults). Each carries a different lifetime cost / convenience / risk profile.

Practicalities

Cost (US, 2024–2025): standard LASIK runs $2,000–3,000 per eye at reputable centres, $4,000–5,000 for premium wavefront-guided or topography-guided LASIK; SMILE $3,000–4,000 per eye; PRK comparable to LASIK; ICL $4,000–5,500 per eye; RLE $4,000–6,500 per eye including the IOL. Insurance does not cover refractive surgery in the US (it is classed as elective). FSA / HSA funds can be applied. Time off work: LASIK 1–2 days; SMILE 1–2 days; PRK 5–7 days; ICL 2–3 days; RLE 2–3 days. Sunglasses, eye shields at night for the first week, and a 2-week pool / hot-tub / makeup pause. Surgeon volume matters: studies consistently show lower complication rates at higher-volume centres Chuck et al. 2018. The single highest-leverage practical choice is the workup — Scheimpflug topography, pachymetry, dry-eye assessment, refraction stability check — not the laser brand.

History

Radial keratotomy (RK) — radial incisions in the cornea, popularised in the Soviet Union by Fyodorov in the 1970s — was the first attempt; long-term hyperopic drift killed it as a mainstream procedure. PRK (excimer laser surface ablation) was FDA-approved in 1995; LASIK followed in 1999 with the femtosecond flap added in the early 2000s. Wavefront-guided ablation arrived mid-2000s; SMILE was CE-marked in 2011 and FDA-approved for moderate myopia in 2016. The cumulative procedure count globally is in the tens of millions, giving the modality one of the largest long-term safety datasets in elective surgery.

Payoff

The dominant lived effect is the absence of an apparatus on the face. Daily-contact wearers describe the recovery of pre-contact morning vision — waking up able to read a clock — as the single sharpest gain. Heavy glasses wearers describe rain, swimming pools, and saunas reverting to ordinary activities. Survey data is consistent: 94–98% of LASIK patients report they would have the procedure again Solomon et al. 2009 Sandoval et al. 2016; satisfaction exceeds long-term contact-lens wearers' satisfaction with their correction Price et al. 2016. The financial break-even versus contacts plus solution plus periodic glasses runs ~7–12 years depending on baseline spend.

Stakes

The honest counter-frame for the eligible reader who declines: lifetime contact lens microbial keratitis risk accumulates linearly — ~1 in 500 person-years for daily wear, ~1 in 100 person-years for extended-wear contacts Stapleton et al. 2008. Over thirty years of daily contacts, the cumulative probability of at least one infection event is non-trivial. Glasses carry no such risk but limit certain activities. The choice is not "surgery risk vs no risk" — it is the one-time procedural risk profile against the ongoing wear risk profile.

Out-of-scope

Pediatric myopia control (atropine, orthokeratology), the optics of glasses lens design (high-index vs Trivex, anti-reflective coatings), and chronic dry-eye treatment beyond the post-LASIK window each warrant separate entries.

Credibility range

Optimist case. Refractive surgery is one of the most-studied elective procedures in medicine. Modern wavefront-guided LASIK, screened with Scheimpflug imaging and dry-eye workup, delivers ≥20/40 vision in >99% of treated eyes and ≥20/20 in 90%+ Sandoval et al. 2016. Patient satisfaction is among the highest reported for any elective procedure: pooled satisfaction ≥95% across decades of literature Solomon et al. 2009, with longitudinal comparison showing LASIK patients more satisfied with their vision than long-term contact-lens wearers Price et al. 2016. The dry-eye signal — historically the strongest objection — is mostly transient in modern femtosecond LASIK and substantially reduced in SMILE Kobashi et al. 2017. Ectasia incidence has fallen by an order of magnitude with topographic screening Chuck et al. 2018. The lifetime risk profile of daily contact lenses is non-trivial and often under-counted in the surgery-vs-status-quo comparison Stapleton et al. 2008. For the right candidate, this is a high-evidence, high-satisfaction, durable intervention.

Skeptic case. The published satisfaction figures rely heavily on surgeon-administered surveys with selection and reporting bias. The FDA's PROWL studies — the most rigorous patient-reported outcomes work — found 41% of patients reported a new visual symptom at 3 months and 28% reported dry-eye symptoms they did not have pre-op Eydelman et al. 2017. The complication tail is real: a meaningful minority experience persistent dry eye, night-vision compromise, or both — and the literature underweights these because they coexist with high overall satisfaction scores. The FDA's 2022 draft labeling proposal would have required disclosure of these patient-level outcomes in plainer language FDA 2022. Ectasia, though rare, is catastrophic when it occurs. The procedure is irreversible (excepting ICL). Marketing-driven volume incentives are a real factor in centre selection. Long-term (>20 year) data is comparatively thin because LASIK volume only ramped after 2000. For a young patient with stable contacts and a modest prescription, "do nothing" is a genuinely reasonable competing call.

Author's call. For a thoroughly screened candidate with stable refraction, healthy corneal topography, no baseline dry eye, and a modality matched to their eye, modern refractive surgery delivers a real, durable lift in daily life with a complication tail that is small but not zero. The right framing is not "safe vs unsafe" but "the workup is the procedure" — the single highest-leverage decision the patient makes is the centre and the candidacy evaluation, not the laser brand or the timing. Honest disclosure of the dry-eye and night-vision risk floor is non-negotiable; readers should be told the modern numbers, not the marketing numbers. Recommend as a decide action, not a do: the candidate-side risk profile is patient-specific in a way that bypasses generic recommendation.

Stakeholder and incentive map

• Commercial — laser device manufacturers (Alcon/WaveLight, Johnson & Johnson Vision/AMO, Zeiss for SMILE, STAAR for ICL), high-volume LASIK chains. Strong incentive to maximise volume and downplay complication rates.
• Professional — American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, European Society of Cataract & Refractive Surgeons. Publish practice patterns and defend the modality against media coverage they consider unrepresentative AAO 2022.
• Regulatory — FDA. Tension with AAO over the 2022 draft labeling; the FDA's PROWL data is the most patient-centric on record Eydelman et al. 2017 FDA 2022.
• Counter-incentive — patient advocacy groups (LASIK Complications Support Group, FDA Citizen Petitions) emphasising the persistent-dry-eye and night-vision minority; some founded by patients with chronic post-LASIK complications. Honest signal under-represented in industry-funded outcomes.
• Optometry — competing economic interests with surgeons (ongoing contact-lens prescriptions vs one-time referral); the modern co-managed care model has partially aligned them.

Population variability

• By refractive error: low-to-moderate myopia (−1 to −6 D) is the best-studied and highest-satisfaction range; high myopia (>−8 D) shifts the right answer toward ICL.
• By corneal anatomy: thin corneas, asymmetric topography, or forme fruste keratoconus are absolute contraindications to LASIK and frequently to SMILE; PRK or ICL is the route.
• By age: 21–40 is the sweet spot — refraction stable, accommodation intact, presbyopia not yet imminent. 40–50: presbyopia approaches; monovision or RLE may be discussed. 50+: RLE / cataract surgery with refractive IOLs becomes the preferred path.
• By baseline tear film: pre-existing meibomian gland dysfunction or Sjögren's predicts worse post-op dry eye; aggressive pre-op treatment helps Toda 2018.
• By occupation: military, athletes, first responders favour PRK or SMILE (no flap to dislocate from blunt trauma).
• By pupil size: large mesopic pupils correlate with night-vision dysphotopsia; modern wavefront-guided ablation with larger optical zones reduces but does not eliminate this.

Knowledge gaps

20+ year outcomes for first-generation LASIK cohorts are still maturing; long-term corneal biomechanical behaviour is incompletely characterised. The neurobiology of post-LASIK chronic dry eye and corneal neuralgia — the small but real minority who develop persistent symptoms — is poorly understood; no validated preoperative screen identifies these patients in advance. The interaction of refractive surgery with subsequent cataract surgery (IOL calculation accuracy in post-LASIK eyes) remains technically demanding. No head-to-head RCT compares modern femtosecond LASIK against SMILE on patient-reported quality-of-life endpoints in a large mixed cohort; the comparison is currently inferred from separate single-arm series.

Scope. The brief named LASIK and refractive surgery; this entry covers all five mainstream modalities (LASIK, SMILE, PRK, ICL, RLE) end-to-end, not just LASIK. Treating it as a LASIK-only piece would mis-route candidates whose right answer is ICL or PRK, so the alternatives section is load-bearing.

Dream tier. Computed overall score is roughly 28 — below the 40 threshold where a dream narrative is obligatory. Wrote one anyway because the wake-up-and-see-the-clock moment is genuinely the sharpest payoff in the catalogue's vision category and the aspiration lever is honest for the right candidate. Cranked the dek and tagline accordingly; held the rest of the article in straight voice.

Action choice. decide rather than do. A multi-thousand-dollar permanent elective procedure with a real complication tail and tight candidacy gating is not "go and do this" advice — the right framing is "the workup decides whether you should have this at all." This shapes the article's centre of gravity (workup-is-the-procedure) and the rejection of the typical do-this guide's tone.

Controversy at 3. The FDA / AAO disagreement over the 2022 draft labeling is genuine, ongoing, and visible to a careful reader. Felt material to surface in the misconceptions section so the reader is not blindsided when they Google. A 4 felt too strong (LASIK is broadly approved and clinically endorsed); a 2 underweights the patient-advocacy minority's signal.

Rating difficulties. Health_short_term was the hardest score. The QoL lift is large for daily contact wearers and modest for occasional glasses wearers; the modern satisfaction literature is strong but mostly surgeon-administered. Landed at 3 anchored on the typical eligible reader (part-time contact wearer). Mood at 2 rather than 3 because vision-related QoL gains are real but not "stabilization of inner life" material. Energy and focus at 1 are honest minor effects — contact-lens-related end-of-day eye fatigue and the marginal sharpness gain — rather than zeros.

Out-of-scope, flagged for future entries. Chronic dry eye as a standalone condition (not just a refractive-surgery side effect); presbyopia and the age-45 reading-glasses transition (an entry of its own — RLE/multifocal IOL choice is part of it); paediatric myopia control (atropine drops, ortho-K, time outdoors); modern cataract surgery and the IOL-selection decision tree (overlaps with RLE but warrants its own entry).

Citations. Added one new ref (Stapleton2008) to anchor the contact-lens microbial keratitis comparison; the remaining sixteen citations were already in the library, which suggests the catalogue has earlier vision work I should review for cross-link candidates.